# NRX Pharmaceuticals

NRX Pharmaceuticals is an Asset Manager based in Radnor, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Radnor, United States
- **Region:** North America
- **Address:** Radnor, PA, United States
- **Assets under management:** Undisclosed
- **Website:** nrxpharma.com
- **LinkedIn:** https://www.linkedin.com/company/nrx-pharma

## Regulatory record

- **Reports private funds:** No

## About

We are NRx – a pioneering and focused CNS biopharma company, dedicated to meeting unmet medical needs for those with suicidal depression, suicidal bipolar depression, and post-traumatic stress disorder (PTSD). The company has filed an Abbreviated New Drug Application (ANDA) for NRX-100, preservative-free IV ketamine and has initiated filing of an NDA for NRX-100 in people with suicidal depression.

## Sectors

- Healthcare Services

## People

- Jonathan Javitt — Chairman and Chief Scientist
- Stephen Willard — Chief Executive Officer

## Questions

### Who controls the clinical and regulatory strategy at NRX Pharmaceuticals?

Dr. Jonathan Javitt, the firm's founder, Chairman, and Chief Scientist, runs clinical and regulatory decisions. He has a public-health career spanning the White House Office of Science and Technology and prior biotech ventures including NeuroRx. CEO Stephen Willard oversees corporate operations and financing. Javitt's academic affiliation with Johns Hopkins informs the firm's clinical-trial design.

### What is the firm's primary asset, and where does it stand with the FDA?

NRX-101, a fixed-dose oral combination of D-cycloserine and lurasidone, is the lead asset targeting suicidal bipolar depression. The FDA has granted it Qualified Infectious Disease Product and Fast Track designations. In July 2024, an independent monitoring board recommended its Phase 2b/3 trial proceed without changes, a signal the study did not require early termination for futility or safety.

### Does NRX have any ownership stake in ketamine manufacturing or supply chain?

NRX does not own manufacturing assets. It has an exclusive supply-chain agreement with Nephron Pharmaceuticals for production of its ketamine-based formulations. The firm's intravenous ketamine, NRX-100, relies on this contract, while clinical supplies for NRX-101 are sourced through standard pharmaceutical manufacturing partnerships.

## Related profiles

- [Union Bankshares](https://altss.com/profile/union-bankshares-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/nrx-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology